The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.

Despite magrolimab’s latest flop, efforts to target CD47 continue.

For now, the group is sticking with what it knows ahead of a big year in lymphoma.

The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.